The IMF’s Understanding series of cancer information booklets is designed to acquaint you with specific multiple myeloma-related tests, treatments and therapies, supportive care measures, and common adverse events.
April 15, 2021
This publication discusses the use of Revlimid (lenalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
July 21, 2023
The Understanding SARCLISA® (isatuximab-irfc) booklet discusses a novel anti-CD38 monoclonal antibody that is approved for patients with relapsed and…
September 21, 2023
The IMF’s Understanding Stem Cell Transplant in Myeloma publication is intended for myeloma patients in the United States who are in discussions with…
November 15, 2023
Talvey is indicated for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 4 prior lines of therapy.
March 16, 2023
Tecvayli™ (teclistmab-cqyv) is the first in a drug class of bispecific antibodies approved by the FDA to treat myeloma.
We Thank Our Sponsors:
BMS, GSK, Janssen Oncology, Sanofi, and Takeda Oncology.